Sharecafe

Chimeric Therapeutics (ASX:CHM) Expands Cancer Trials

Chimeric Therapeutics CEO / MD Jennifer Chow provides an update on clinical trial progression and discusses recent agreements with WuXi Advanced Therapies and Be The Match BioTherapies.

Chimeric Therapeutics Limited (ASX:CHM) CEO and Managing Director Jennifer Chow provides an update on clinical trial progression, and discusses recent agreements with WuXi Advanced Therapies and Be The Match BioTherapies.

Serving up fresh finance news, marker movers & expertise.
LinkedIn
Email
X

All Categories